Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01904734
Other study ID # VETSCLOMIDPHX
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2012
Est. completion date October 31, 2018

Study information

Verified date March 2021
Source Phoenix VA Health Care System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to explore whether men with low testosterone levels, due to altered brain regulation of male hormone function, who have been previously treated with testosterone, respond as well as men who have not been so treated to clomiphene citrate, an agent commonly used for female infertility that has been shown to improve male hormone secretion in some cases.


Description:

Clomiphene, an oral FDA-approved agent for female infertility has been shown to normalize testosterone levels in men with hypogonadotropic hypogonadism. It appears to be safe and well tolerated. This study will compare testosterone responses to clomiphene citrate in male veterans with hypothalamic hypogonadism naïve to treatment with responses of similar patients already receiving treatment with injectable or transdermal testosterone. This is an open-label, prospective, interventional trial to be conducted in an outpatient specialty care setting. We will randomize 64 hypogonadal male veterans evenly divided between naive and previous treatment and treat for 8 weeks with clomid, increasing the initial dose of 25 mg to 50 mg/day in those who fail to achieve target testosterone level (450 ng/dl) after the first 3 weeks. Endpoint measurements performed in the Phoenix VA Health Care System (PVAHCS) clinical laboratory will be total testosterone as well as bioavailable testosterone and sex hormone binding globulin. Total testosterone level at 8 weeks of treatment will be reported as the primary endpoint. Safety measures (CBC,liver functions, PSA) will be assessed at 8 weeks as well. This study will help serve as a guide for design of future studies of clomiphene in hypogonadal men.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date October 31, 2018
Est. primary completion date October 31, 2018
Accepts healthy volunteers No
Gender Male
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria: - Patient or eligible for care at Phoenix VA Health Care System - Male ages 30-70 years - testosterone level below 250 ng/dl before treatment - able to provide informed written consent Exclusion Criteria: - evidence of pituitary tumor >1mm by MRI or CAT scan - chronic illness (renal, cardiac, liver failure) - Prostate specific antigen (PSA) >4.0 ng/ml - history of prostate, breast, or testicular cancer - eye disease compromising vision (e.g. cataracts)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Clomiphene
Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks

Locations

Country Name City State
United States Phoenix VA Health Care System Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
Phoenix VA Health Care System

Country where clinical trial is conducted

United States, 

References & Publications (3)

Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012 Aug;110(4):573-8. doi: 10.1111/j.1464-410X.2011.10702.x. Epub 2011 Nov 1. — View Citation

Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int. 2012 Nov;110(10):1524-8. doi: 10.1111/j.1464-410X.2012.10968.x. Epub 2012 Mar 28. — View Citation

Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010 Jan;7(1 Pt 1):269-76. doi: 10.1111/j.1743-6109.2009.01454.x. Epub 2009 Aug 17. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Total serum testosterone laboratory measurement by standard immunometric method at the end of 8 weeks of treatment
Secondary Bioavailable testosterone Non-SHBG bound testosterone by ammonium sulfate precipitation method at the end of 8 weeks of treatment
Secondary Serum sex hormone binding globulin (SHBG)level Laboratory measurement of SHBG by standard immunometric technique at the end of 8 weeks of treatment
See also
  Status Clinical Trial Phase
Completed NCT04467697 - Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men Phase 3
Completed NCT04326673 - Salivary Testosterone in Men: Diurnal Variation and Post-Prandial Responses
Completed NCT03203681 - Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Phase 4
Completed NCT00398580 - 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men Phase 2
Completed NCT00400335 - Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride Phase 1
Recruiting NCT05611307 - Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Completed NCT03282682 - Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male N/A
Terminated NCT03335254 - A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males Phase 1/Phase 2
Terminated NCT05205837 - A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial Phase 4
Completed NCT03747003 - Gonadal Function in Young to Middle Aged HIV-infected Men
Withdrawn NCT03176537 - Periodontal Profile of Hypogonadic Men Phase 4
Recruiting NCT04049331 - Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone Phase 2
Completed NCT03541395 - Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males N/A
Recruiting NCT05249634 - Testosterone Treatment in Men With Chronic Kidney Disease Phase 2
Not yet recruiting NCT05773183 - Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Withdrawn NCT04717362 - The Effects of Natesto For Treatment Of Hypogonadism Early Phase 1
Completed NCT05806723 - Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men Phase 4
Completed NCT04456296 - A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism Phase 4
Not yet recruiting NCT06312761 - Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 Phase 1/Phase 2
Recruiting NCT05381831 - Natesto Spermatogenesis Reboot Phase 4